Wells Fargo’s Trillium Therapeutics Inc. TRIL Stock Holding History

Wells Fargo’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,900	Closed	-$51K	–	8280
2021 Q3	$51K	Buy	+2,900	New	+$33.9K	﹤0.01%	5623

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Wells Fargo's TRIL Position: Q4 2021 in Review

Wells Fargo sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 4,620 shares — an estimated $81K sold.

Wells Fargo first reported a position in TRIL in Q3 2015 and held it in 25 quarters. The position peaked at $216K in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Wells Fargo reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Wells Fargo sold 4,620 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $81K.
Wells Fargo first reported a position in Trillium Therapeutics Inc. in Q3 2015 and held it in 25 quarters.
Wells Fargo's Trillium Therapeutics Inc. position peaked at $216K in Q4 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Wells Fargo's 13F filing for Q4 2021, filed 14 Feb 2022.